What Matters to Patients and Clinicians when Discussing the Impact of Cancer Medicines on Health-related Quality of Life? Consensus-based Mixed Methods Approach in Prostate Cancer

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2021 Dec 8

PMID 34878587

Citations 4

Authors

Emma Dunlop

Aimee Ferguson

Tanja Mueller

Kelly Baillie

Julie Clarke

Jennifer Laskey

Amanj Kurdi

Olivia Wu

Rob Jones

Hilary Glen

Marion Bennie

Affiliations

Soon will be listed here.

Abstract

Objective: To identify what matters to clinicians and patients when discussing cancer medicines' impact on health-related quality of life (HRQoL).

Methods: A framework of HRQoL domain/domain elements was developed, informed by analysis of published patient reported outcome measures (PROMs), applicable to prostate cancer. Using mixed methods (eDelphi, Nominal Group Technique and questionnaire), prostate cancer clinicians and patients attending prostate cancer clinics and support groups were asked which domains/domain elements would be important to them when discussing the impact prostate cancer medicines have on their HRQoL.

Results: Twenty-one clinicians and 71 patients participated from the West of Scotland. Clinicians and patients identified 53/62 domain elements across seven domains as important, of which 32 (60%) were common to both groups. Clinicians placed more importance than patients on Mood & Emotion; in contrast, patients placed importance on a broader range of Symptoms & Side Effects, being informed about their care, and having effective healthcare professional collaboration.

Conclusion: This study provides insight into the similarities and differences between what clinicians and patients think is important when discussing the impact of cancer medicines on HRQoL. Future research should involve exploring the potential for consistency of medicines PROMs across different cancer types to support patient-clinician communication and drive improvements in care.

Citing Articles

Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005-2020: an observational study.

Zhang L, Zhang Y, Li H, Shi L, Guan X Lancet Reg Health West Pac. 2024; 46:101077.

PMID: 38721064 PMC: 11077018. DOI: 10.1016/j.lanwpc.2024.101077.

Fatigue in Prostate Cancer: A Roundtable Discussion and Thematic Literature Review.

Cornford P, Robijn E, Rogers E, Wassersug R, Fleure L Eur Urol Open Sci. 2024; 63:119-125.

PMID: 38596782 PMC: 11001642. DOI: 10.1016/j.euros.2024.03.003.

Involving Patients and Clinicians in the Design of Wireframes for Cancer Medicines Electronic Patient Reported Outcome Measures in Clinical Care: Mixed Methods Study.

Dunlop E, Ferguson A, Mueller T, Baillie K, Laskey J, Clarke J JMIR Form Res. 2023; 7:e48296.

PMID: 38127422 PMC: 10767627. DOI: 10.2196/48296.

Testosterone Replacement Therapy in the Aged Male: Monitoring Patients' Quality of Life Utilizing Scoring Systems.

Tsampoukas G, Pang K, Papatsoris A, Moussa M, Miah S Int J Gen Med. 2022; 15:7123-7130.

PMID: 36105846 PMC: 9464626. DOI: 10.2147/IJGM.S253183.

References

Penson D, Rossignol M, Sartor A, Scardino P, Abenhaim L . Prostate cancer: epidemiology and health-related quality of life. Urology. 2008; 72(6 Suppl):S3-11. DOI: 10.1016/j.urology.2008.10.006. View

Dellis A, Zagouri F, Liontos M, Mitropoulos D, Bamias A, Papatsoris A . Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. Cancer Treat Rev. 2019; 73:54-61. DOI: 10.1016/j.ctrv.2018.11.005. View

Estwing Ferrans C, Zerwic J, Wilbur J, Larson J . Conceptual model of health-related quality of life. J Nurs Scholarsh. 2006; 37(4):336-42. DOI: 10.1111/j.1547-5069.2005.00058.x. View

Basch E, Deal A, Dueck A, Scher H, Kris M, Hudis C . Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017; 318(2):197-198. PMC: 5817466. DOI: 10.1001/jama.2017.7156. View

Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A . Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017; 359:j4530. PMC: 5627352. DOI: 10.1136/bmj.j4530. View

Atkinson T, Li Y, Coffey C, Sit L, Shaw M, Lavene D . Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2011; 21(7):1159-64. PMC: 3633532. DOI: 10.1007/s11136-011-0031-4. View

Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris M . Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006; 7(11):903-9. DOI: 10.1016/S1470-2045(06)70910-X. View

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M . Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009; 101(23):1624-32. PMC: 2786917. DOI: 10.1093/jnci/djp386. View

Brunelli C, Costantini M, Di Giulio P, Gallucci M, Fusco F, Miccinesi G . Quality-of-life evaluation: when do terminal cancer patients and health-care providers agree?. J Pain Symptom Manage. 1998; 15(3):151-8. DOI: 10.1016/s0885-3924(97)00351-5. View

10.

Chandwani K, Zhao F, Morrow G, Deshields T, Minasian L, Manola J . Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables. J Pain Symptom Manage. 2017; 53(6):988-998. PMC: 5474148. DOI: 10.1016/j.jpainsymman.2016.12.347. View

11.

Nekolaichuk C, Bruera E, Spachynski K, MacEachern T, Hanson J, Maguire T . A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med. 2000; 13(4):311-23. DOI: 10.1191/026921699675854885. View

12.

Efficace F, Feuerstein M, Fayers P, Cafaro V, Eastham J, Pusic A . Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. Eur Urol. 2013; 66(3):416-27. PMC: 4150854. DOI: 10.1016/j.eururo.2013.10.017. View

13.

Velikova G, Booth L, Smith A, Brown P, Lynch P, Brown J . Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004; 22(4):714-24. DOI: 10.1200/JCO.2004.06.078. View

14.

Roberts N, Alexander K, Wyld D, Janda M . Statistical process control assessed implementation fidelity of patient-reported outcome measures (PROMs) in routine care. J Clin Epidemiol. 2020; 127:76-86. DOI: 10.1016/j.jclinepi.2020.06.022. View

15.

Calvert M, Kyte D, Price G, Valderas J, Hjollund N . Maximising the impact of patient reported outcome assessment for patients and society. BMJ. 2019; 364:k5267. DOI: 10.1136/bmj.k5267. View

16.

Black N, Burke L, Forrest C, Sieberer U, Ahmed S, Valderas J . Patient-reported outcomes: pathways to better health, better services, and better societies. Qual Life Res. 2015; 25(5):1103-12. DOI: 10.1007/s11136-015-1168-3. View

17.

Camuso N, Bajaj P, Dudgeon D, Mitera G . Engaging Patients as Partners in Developing Patient-Reported Outcome Measures in Cancer-A Review of the Literature. Support Care Cancer. 2016; 24(8):3543-9. DOI: 10.1007/s00520-016-3151-0. View

18.

Caram M, Wang S, Tsao P, Griggs J, Miller D, Hollenbeck B . Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer. Urol Pract. 2019; 6(4):234-242. PMC: 6605774. DOI: 10.1097/UPJ.0000000000000020. View

19.

Jones J, Hunter D . Consensus methods for medical and health services research. BMJ. 1995; 311(7001):376-80. PMC: 2550437. DOI: 10.1136/bmj.311.7001.376. View

20.

Marino L, Johnson M, Hall N, Davies N, Kidd C, Daniels M . The development of a consensus-based nutritional pathway for infants with CHD before surgery using a modified Delphi process. Cardiol Young. 2018; 28(7):938-948. PMC: 5977758. DOI: 10.1017/S1047951118000549. View